Under the new policy of medical reform, pharmaceutical distribution enterprises have accelerated their transformation!

[Pharmaceutical Network Market Analysis] In recent years, with the promotion of a series of new policies such as the abolition of drug mark-up, the two-invoice system, volume purchases, and medical insurance reform, the profit margins of the pharmaceutical distribution industry have been continuously squeezed
.

In October 2021, the Ministry of Commerce issued the "Guiding Opinions on Promoting the High-Quality Development of the Pharmaceutical Circulation Industry during the "14th Five-Year Plan" Period", encouraging enterprises in the pharmaceutical circulation industry to grasp the chain, specialization, diversification and specialization of pharmaceutical retail.
The development trend is to be more refined and specialized, bigger and stronger, to meet the needs of the multi-level healthy consumer market
.

In this context, the pace of transformation of enterprises in the pharmaceutical distribution industry has been further accelerated
.

Up to now, there are 34 listed pharmaceutical distribution companies in the A-share market.
Under the new pharmaceutical policy, some pharmaceutical distribution companies have chosen to extend to upstream pharmaceutical companies, while others have actively deployed the downstream self-operated pharmacy market
.

For example, Nanjing Pharmaceuticals has actively shifted its role from circulation to operation in recent years, and has accelerated the pace of innovative Internet+, gradually forming two innovative systems of modern supply chain services for medical institutions and pharmaceutical retail chain services
.

In the first half of 2021, Nanjing Pharmaceutical continued to improve the company's "14th Five-Year Plan" strategic development plan and formulated several special plans to promote technological innovation and digital transformation of the company's main business
.

Under the "Internet +" new pharmaceutical retail model, the growth of the company's retail e-commerce business far exceeds the growth of traditional offline stores
.

The company has stated that under a clear development strategy, around the goal of improving value to increase market value, standardize operations, adhere to the concept of "performance is king" and further promote enterprise transformation and innovation, continue to optimize business models and profitability, and improve.
Operating efficiency and capital gains, and continuously improve the comprehensive strength of the enterprise
.

By vigorously developing the new retail model of professional pharmacies, Dajia Weikang actively explores "Internet +" prescription drug retail, and gradually transforms from a traditional drug distribution service to a smart medical service provider that provides comprehensive services such as medical consultation, chronic disease management, and medical distribution.
An open and shared big health ecosystem with data as the link has been established
.

 　　Jointown also complies with policy and market changes, actively explores innovative development models, and improves business efficiency and service quality
.

Recently, the company has also made it clear that digital transformation will continue to be promoted as a long-term work, and has released a strategic blueprint to accelerate the process of building a digital JOZHOU, and achieve the "experience improvement, cost reduction and efficiency enhancement, precise decision-making, and model innovation" for the digital transformation of pharmaceutical companies.
Kyushu Model"
.

Among them, 2022 is a key year for the company's transformation.
Jointown will focus on 16 digital sub-projects, involving various aspects such as corporate internal control, customer service experience improvement, and external business empowerment
.

 　　In general, digital transformation is the direction of the transformation of most pharmaceutical distribution companies, and it is also the general trend of industry development
.

The industry predicts that with the advancement of the centralized procurement policy, the concentration of the pharmaceutical distribution industry will increase rapidly in the future.
Pharmaceutical distribution enterprises that have actively transformed and staking their ground may usher in accelerated development, while small and medium-sized pharmaceutical distribution enterprises that do not keep pace with the times are under pressure.
may increase day by day
.

 　　Essence Securities has previously pointed out in a research report that due to their scale and financial strength, the leading pharmaceutical distribution companies will have more say in mergers and acquisitions, and the future is expected to present a situation where the strong will remain strong
.

 　　Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.